Latest United States News

Talga has begun commercial deliveries of Swedish-made Talnode-C to Nyobolt, marking a shift from customer qualification to ongoing supply. The ASX-listed battery materials developer also advanced a 2,000-tonne-per-year Japanese offtake pathway, but ended September with A$10.8 million in cash after A$7.6 million of operating and investing outflows.

Peak Processing has kept Group EBITDA positive for a second consecutive quarter while reducing operating cash outflow by about 79% to A$317,000. The improvement comes with lower quarterly revenue, A$813,000 of cash and fully drawn debt facilities, leaving execution in the December quarter crucial.

FBR has converted its first Mantis welding robot sale into a binding A$990,000 order and secured a North American distributor. The commercial progress comes alongside A$2.073 million of quarterly operating cash burn and a reported 0.12 quarters of funding at period end.

Hastings Technology Metals has completed its 49% Thai processing plant acquisition and is targeting first mixed rare earth chloride production in the June 2027 quarter. But the company ended September with A$1.85 million in cash, leaving funding the immediate test for both its downstream strategy and Yangibana development.

Visionflex ended the September quarter with A$657,000 in cash and estimated funding for just 2.1 quarters, while aged care subscription losses drove a 25% fall in reported ARR. Revenue edged higher and costs improved, but the company now needs hardware wins to become recurring income before liquidity tightens further.

Fulcrum Lithium has delivered a 10.7 million tonne lithium carbonate equivalent resource at Alkali Flats, while advancing acid-free extraction tests and securing approval to drill Dry Canyon. The progress comes with only A$875,000 in cash and no stated plan to raise more funds.

Recce Pharmaceuticals has cleared an active-comparator design for its pivotal Australian diabetic foot infection trial while an independent review of Indonesian Phase 3 data approaches. The biotech ended the quarter with A$1.04 million in cash, alongside expected tax rebates and unused financing facilities.

Paradigm Biopharmaceuticals’ pivotal knee osteoarthritis trial fell below its pre-specified continuation threshold, leaving the ASX-listed biotech in voluntary administration with A$4.33 million in cash. Administrators now have up to three months to assess restructuring options, clinical data and the company’s future.

Spectur closed the September quarter with $762,000 in cash after a $1.10 million operating outflow, leaving it with an estimated 0.69 quarters of funding. The company is relying on cost savings, stronger seasonal receipts, collections of $1.1 million in receivables and a proposed $770,000 R&D tax credit advance to improve liquidity.

Terragen has completed the induction of 10,600 cattle into its largest feedlot trial and secured Brazilian approval for its probiotic feed additive. But customer receipts fell to $255,000 for the September quarter, while cash declined to $5.73 million amid a CEO departure and chair transition.

Volt Resources has secured US$5.4 million in fully funded support for its Alabama graphite strategy, but ended the September quarter with only A$170,000 in cash. The company is also managing lower-than-planned Ukrainian production, cancelled Tanzanian mining licences and a partly conditional A$1.5 million capital raising.

Victory Metals has put a A$1.21 billion post-tax PFS value on North Stanmore, secured its mining lease and begun product qualification with potential offtake partners. The project remains pre-production, with DFS work, approvals, financing and metallurgical validation still ahead.